Company / Cost of Revenue
IOVANCE BIOTHERAPEUTICS, INC. Cost of Revenue History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$173.2M
FY2025
5-year range
$1.0M / $173.2M
FY2023-FY2025
Trend
+85.7%
vs FY2024
Sector context
#39 of 85
Health Care
What the data says
At $173M, IOVANCE BIOTHERAPEUTICS, INC.'s cost of revenue ranks #47 of 85 in the Health Care sector. Increased from $1M to $173M over the past 2 years.
Based on SEC 10-K filings.
$173M in FY2025.
Increased from $1M to $173M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#47 of 85 in Health CareTop 54% of 85This company $173.2M Sector average $2.0B
▼
-91.3% below sector average
Key checks
Key Insights
- In FY2025, cost of revenue increased 85.7% year-over-year.
- Ranks #39 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $173.2M | +85.7% |
| FY2024 | $93.2M | +8926.9% |
| FY2023 | $1.0M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026